Wellcome Trust Sanger Institute
Genome Research Limited
Wellcome Trust Genome Campus
Dr. Richard Durbin
Dr. Harold Swerdlow
Dr. Anja Kolb-Kokocinski
The Wellcome Trust Sanger Institute (WTSI; http://www.sanger.ac.uk) is a not-for-profit research organisation and one of the foremost genome centres in the world. It contributed one third of the reference human genome sequence, has sequenced the genomes of many other species, and made significant contributions many other large international projects including the HapMap project and the WTCCC. With a faculty of 35 investigators, it is currently dedicated to the functional analysis of genomes through sequencing and other genomic techniques, human genetics and human, mouse and pathogen genetics. The Sanger Institute currently has the largest second generation sequencing capacity worldwide including 40 machines spanning three commercially available platforms. It is also currently directly involved in human genetics studies totalling over 100,000 primary samples. Genomic analysis is complemented by computational interpretation and experimental analysis of gene function in a variety of model organisms. There are designated teams for library preparation, sequencing production and data processing. The data centre for computation and data distribution has recently been extended and now has at least 3000 terabytes of storage space available and a computer farm consisting of over 5,000 CPUs. This is the largest biological computing facility in Western Europe.
The WTSI will be involved in the three major areas of ESGI, Networking (WP2, WP4, WP6), Research (WP9 and WP10) and together with all the other partners in Transnational Access (WP8). The WTSI will help to develop and harmonise protocols for sample processing including library making, methods and standards for data management, processing and exchange for new tech sequencing data. The WTSI will also host on-site workshops for interested participants. In the area of Research the WTSI will improve pull-down methods, including high complexity barcoding and no-PCR library making as well as implementing 3rd generation sequencing tools.
The involvement in WP8 will include
- Exome sequencing of European Biobank samples selected for cardiovascular and other quantitative traits, to identify genes and rare variants involved in those traits
- Genome-wide sequencing of samples from isolated populations (e.g. from EUROSPAN) to identify variants in the founders of these populations to be imputed into other population members